Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - trihexyphenidyl (benzhexol) hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; calcium hydrogen phosphate dihydrate; maize starch - as an adjunct in the therapy of all forms of parkinsonism (postencephalitis, artencephalitis, arteriosclerotic and idiopathic). it is useful in the prevention or control of extrapyramidal disorders due to cns drugs such as phenothiazines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 29.12 mg (equivalent: tapentadol, qty 25 mg) - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; purified talc; macrogol 6000; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; indigo carmine aluminium lake; maize starch; colloidal anhydrous silica; hyprolose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hyprolose; indigo carmine aluminium lake; microcrystalline cellulose; maize starch; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hyprolose; magnesium stearate; maize starch; microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: maize starch; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; microcrystalline cellulose; hyprolose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hyprolose; lactose monohydrate; magnesium stearate; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; indigo carmine aluminium lake; maize starch; hyprolose; magnesium stearate; microcrystalline cellulose - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; microcrystalline cellulose; maize starch; iron oxide yellow; magnesium stearate - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; hyprolose; lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.